

Applicant: Ridwan Shabsigh
Serial No.: 10/658,991
Filed: September 9, 2003
Page 2

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application pursuant to 37 C.F.R. § 1.121:

Listing of Claims

1-8. (Canceled)

9. (Currently Amended) A method for increasing or maintaining the blood supply in the penis of a subject afflicted by vasculogenic erectile dysfunction which method comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a cell of the corpora cavernosa of the subject's penis under conditions permitting the expression of the vascular endothelial growth factor encoded by the introduced nucleic acid in the cell so as to thereby express the vascular endothelial growth factor in the corpora cavernosa so as to thereby increase or maintain the levels of vascular endothelial growth factor so as to effect vasculogenesis and thereby increase or maintain the blood supply in the subject's penis.

10. (Previously Presented) The method of claim 9, wherein the nucleic acid is contained within a vector.

11. (Canceled)

12. (Canceled)

13. (Previously Presented) The method of claim 9, wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.

14-17. (Canceled)

18. (Previously Presented) A method for treating vasculogenic erectile dysfunction in a subject so afflicted which method comprises introducing a nucleic acid comprising a gene encoding a vascular endothelial growth factor into a cell of the corpora cavernosa of the subject's penis so as to express the vascular endothelial growth factor encoded by the introduced nucleic acid in the cell, thereby increasing or maintaining the levels of vascular endothelial growth factor in the corpora cavernosa so as to effect vasculogenesis and thereby treat erectile dysfunction in the subject.

19. (Previously Presented) The method of claim 18, wherein the nucleic acid is contained within a vector.

20. (Canceled).

21. (Previously Presented) The method of claim 18, wherein the wherein the vascular endothelial growth factor is VEGF-A 205/206, VEGF-A 188/189, VEGF-A 164/165, VEGF-A 144/145, VEGF-A 120/121, or VEGF-A 110.